Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: February 7, 2023

Details for Patent: 9,840,505

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,840,505 protect, and when does it expire?

Patent 9,840,505 protects COPIKTRA and is included in one NDA.

This patent has forty patent family members in twenty-three countries.

Summary for Patent: 9,840,505

Title:	Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Abstract:	Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
Inventor(s):	Ren; Pingda (San Diego, CA), Martin; Michael (San Marcos, CA), Isbester; Paul (Castleton, NY), Lane; Benjamin S. (Lynnfield, MA), Kropp; Jason (Westford, MA)
Assignee:	Infinity Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	15/016,117
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,840,505

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)	See Plans and Pricing
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)	See Plans and Pricing
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-002	Sep 24, 2018		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)	See Plans and Pricing
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-002	Sep 24, 2018		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,840,505

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	084824	See Plans and Pricing
Argentina	117467	See Plans and Pricing
Australia	2012205669	See Plans and Pricing
Australia	2015258280	See Plans and Pricing
Brazil	112013017670	See Plans and Pricing
Canada	2824197	See Plans and Pricing
Chile	2013002007	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

Express Scripts

McKinsey

Moodys

Dow

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.